Pharos IBio Co (XKRX:388870) ROCE % : -44.42% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharos IBio Co's annualized ROCE % for the quarter that ended in Mar. 2024 was -44.42%.

Pharos IBio Co ROCE % Historical Data

The historical data trend for Pharos IBio Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co ROCE % Chart

Pharos IBio Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-38.26

Pharos IBio Co Quarterly Data
	Mar22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial			-67.64	-48.85	-39.71	-31.37	-44.42

Pharos IBio Co ROCE % Calculation

Pharos IBio Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8847.121	/	( ( (18721.329 - 950.949)	+	(29690.25 - 1213.344) )	/ 2 )
	=	-8847.121	/	( (17770.38	+	28476.906)	/ 2 )
	=	-8847.121	/	23123.643
	=	-38.26 %

Pharos IBio Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-12011.976	/	( ( (29690.25 - 1213.344)	+	(26656.974 - 1047.308) )	/ 2 )
	=	-12011.976	/	( ( 28476.906	+	25609.666 )	/ 2 )
	=	-12011.976	/	27043.286
	=	-44.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Pharos IBio Co (XKRX:388870) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharos IBio Co ROCE % Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharos IBio Co (XKRX:388870) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR

Website

https://www.pharosibio.com

Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co (XKRX:388870) Headlines

No Headlines